Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts

European Journal of Dermatology

Volumn 16, Issue 6, 2006, Pages 642-648

  Schöfer, Helmut ^a   Van Ophoven, Arndt ^b   Henke, Ulrike ^a   Lenz, Tamara ^c   Eul, Angelika ^d  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Statistical Consulting   (Germany)

^d Medical Consulting   (Germany)

Author keywords

Ablative therapy; Anogenital warts; Comparative trial; Imiquimod 5 cream; Recurrence rate; Sustained efficacy

Indexed keywords

IMIQUIMOD;

ADULT; APPLICATION SITE PAIN; ARTICLE; BURNING SENSATION; CAUTERIZATION; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ECZEMA; ERYTHEMA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LOCAL SKIN REACTION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT DISEASE; SKIN SURGERY; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AMINOQUINOLINES; ANUS DISEASES; FEMALE; FOLLOW-UP STUDIES; GENITAL DISEASES, FEMALE; GENITAL DISEASES, MALE; HUMANS; MALE; SAFETY; WARTS;

EID: 33846805903     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0013     Document Type: Article

References (12)

1. von Krogh G, Lacey CJN, Gross G, Barrasso R, Schneider A. European course on HPV-associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Inf 2000; 76: 162-8.
2. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001; 11(6): 598-603.
3. Beutner KR, Wiley DJ. Recurrent external Genital Warts: A Literature Review. Papillomavirus Report 1997; 8(3): 69-74.
4. Edwards L, Ferenzcy A, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA. Self-administered Topical 5% Imiquimod Cream for External Genital Warts. Arch Dermatol 1998; 134: 25-30.
5. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998; 38: 230-9.
6. Stanley MA. The Imidazochinolines-mechanism of action and therapeutic potential in HPV-associated disease. Papillomavirus Report 2005; 16(3): 141-6.
7. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HBA. Randomised, Controlled, Molecular Study of Condylomata acuminata Clearance During Treatment with Imiquimod. J Infect Dis 1998; 178: 551-5.
8. Hoyme UB, Hagedorn M, Schindler A-E, Schneede P, Hopfenmüller W, Schorn K, EuI A. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol 2002; 10: 79-88.
9. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomized clinical trial comparing podophyllin, cryotherapy, and electrodesiccation. Genitourin Med 1990; 66: 16-9.
10. Czelusta AJ, Evans T, Arany I, Tyring SK. A guide to Immunotherapy of Genital Warts - Focus on Interferon and Imiquimod. BioDrugs 1999; 11(5): 319-32.
11. Hemmi H, Kaisho T, Takeuchi O. Small antiviral compounds activate immune cells via the TLR7 MyD88-signaling pathway. Nat Immunol 2002; 3(2): 196-200.
12. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, Miller RL, Souder DN. Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells. J Invest Dermatol 2000; 114: 135-41.